Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CUE 221

Next Previous
Drug Profile

CUE 221

Alternative Names: Ascendant-221; CUE-221; UB 221

Latest Information Update: 10 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ascendant Health Sciences; Chinese Academy of Sciences
  • Developer Chinese Academy of Sciences; United BioPharma
  • Class Anti-inflammatories; Antiallergics; Immunotherapies; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action IgE receptor antagonists; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic urticaria
  • Clinical Phase Unknown Allergic asthma; Allergic rhinitis; Atopic dermatitis; Food hypersensitivity

Most Recent Events

  • 03 Aug 2026 Cue Biopharma files an IND application with the US FDA for Food hypersensitivity
  • 15 May 2026 Cue Biopharma announces an intention to submit an Investigational New Drug (IND) amendment to the US FDA to expand development into Food hypersensitivity in the second half of 2026
  • 15 May 2026 Cue Biopharma Plans a global phase IIb trial in Food hypersensitivity

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top